IRF2 Destabilizes Oncogenic KPNA2 to Modulate the Development of Osteosarcoma

Figure 2

Identification of KPNA2 transcription factor (TF) (a) Venn diagram displayed the overlap among differentially expressed protein-coding genes (DEGs) from GSE157322, KPNA2 negative-related genes from TARGET dataset and TF factors of KPNA2 from online TFBIND dataset. (b) The mRNA expression of KPNA2 in response to overexpression of five candidate genes (RFX1, STAT3, IRF2, PPARA, and MZF1) in U2OS and MG-63 cells. (c) The mRNA expression of five candidate genes (RFX1, STAT3, IRF2, PPARA, and MZF1) in response to KPNA2 silence in U2OS and MG-63 cells. (d) Expression of IRF2 mRNA in OS and nontumor tissues based on data from GSE36001 dataset. (e) The negatively correlation between KPNA2 and IRF2 was analyzed under a Pearson correlation analysis according to TARGET database. (f) IRF2 mRNA expression in 25 pairs of OS and normal samples. (g) The enrichment of IRF2 bind on the KPNA2 promoter was significantly reduced in two OS cell lines when compared to hFOB1.19 cells from ChIP and qRT-PCR assays. (h) Luciferase assays were performed to detect the luciferase activity of KPNA2-WT and KPNA2-MUT after IRF2 overexpression in U2OS and MG-63 cells. The data was presented as the from three independent experiments , , and .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)